webinar register page

Webinar banner
Learn how you can be a founding investor in the future of epilepsy care.


Jul 30, 2021 01:45 PM

* Required information


Rachel Kuperman, M.D.
Founder & CEO @Eysz
Dr. Kuperman is a pediatric neurologist with dual certification in epilepsy and neurology with over 10 years’ experience directing the clinical epilepsy and research program at UCSF Benioff Children’s Hospital, Oakland where she developed the epilepsy program by focusing on excellence in clinical care and research. She stepped back from that role, having secured multiple grants and published more than two dozen peer reviewed publications, to found Eysz. Eysz comes out of her clinical work to help parents, caregivers and physicians quantitate the burdens of epilepsy: seizures and neurocognitive side effects.
Danielle Marano
Chief Executive Officer @The Hundley Foundation
Danielle Marano has been involved in the non-profit field for over eleven years. Most recently in her past role as the Executive Director of the Epilepsy Foundation of Nevada. Prior to her arrival, Nevada had no resources or support for patients and families receiving a diagnosis of epilepsy. In 2009 Danielle and a small group of volunteers built a community providing help, education and support for families. Over the next seven years that small group of people turned into thousands served throughout Nevada. Danielle’s work in the epilepsy field is extremely personal to her as she was diagnosed with generalized epilepsy at age thirteen. For over ten years she struggled to gain seizure control. After many failed medications, her team of doctors finally found a combination that worked to control her seizures.
Neil J. Littman, M.S.
Founder, CEO & Managing Director @Bioverge, Inc.
Neil Littman has comprehensive healthcare-specific financial experience in venture philanthropy and investment banking. As a member of the Executive Leadership Team and Director of Business development at the California Institute for Regenerative Medicine (CIRM), Neil managed more than 40 clinical stage stem cell and regenerative medicine therapies totaling over $500 million. Neil was also previously the Vice President of Business Development at Notable Labs, an oncology-focused startup where he led the development of global corporate partnerships through the successful completion of the companies’ $40 million Series B financing. Neil started his career on Wall Street as an investment banker at Deutsche Bank and Thomas Weisel Partners, where he advised emerging growth biotech companies on public and private financings, licensing, M&A and other transactions over $1 billion.